Search Results - "Blakely, Johnetta"

Impact of early detection on cancer curability: A modified Delphi panel study by Schwartzberg, Lee, Broder, Michael S, Ailawadhi, Sikander, Beltran, Himisha, Blakely, L Johnetta, Budd, G Thomas, Carr, Laurie, Cecchini, Michael, Cobb, Patrick, Kansal, Anuraag, Kim, Ashley, Monk, Bradley J, Wong, Deborah J, Campos, Cynthia, Yermilov, Irina

“…Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a…”
Get full text

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer by KARP, Daniel D, PAZ-ARES, Luis G, JOHNSON, Faye M, GREEN, Stephanie, GUALBERTO, Antonio, NOVELLO, Silvia, HALUSKA, Paul, GARLAND, Linda, CARDENAL, Felipe, JOHNETTA BLAKELY, L, EISENBERG, Peter D, LANGER, Corey J, BLUMENSCHEIN, George

“…We conducted a phase II study of combination of the anti-insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in…”
Get full text

Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model by Wirtz, Heidi S, Hepp, Zsolt, Grewal, Simrun, Wright, Phoebe, Fuldeore, Rupali, Tomicki, Samantha, Hirsch, Jared, Dieguez, Gabriela, Blakely, L Johnetta

“…New and emerging therapies have significantly changed the bladder cancer (BC) treatment landscape and can potentially affect spending and patient care in CMS'…”
Get full text

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, SMIT, Egbert F, JASSEM, Jacek, DEDIU, Mircea, SHENGYAN HONG, VISSEREN-GRUL, Carla, HANAUSKE, Axel-Rainer, OBASAJU, Coleman K, GUBA, Susan C, THATCHER, Nick, LORIGAN, Paul, KONDURI, Kartik, RECK, Martin, SZCZESNA, Aleksandra, BLAKELY, Johnetta, SERWATOWSKI, Piotr, KARASEVA, Nina A, CIULEANU, Tudor

“…Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was…”
Get full text

Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy by Dickson, Natalie R, Beauchamp, Karen D, Perry, Toni S, Roush, Ashley, Goldschmidt, Deborah, Edwards, Marie Louise, Blakely, L Johnetta

“…Background Utilization of electronic patient-reported outcome (ePRO) tools to monitor symptoms in patients undergoing cancer treatment has shown clinical…”
Get full text

The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer by Stepanski, Edward J, Walker, Mark S, Schwartzberg, Lee S, Blakely, L Johnetta, Ong, Jason C, Houts, Arthur C

“…To evaluate the relation among several symptoms that occur commonly in cancer patients: trouble sleeping, fatigue/sleepiness, depressed mood, and pain in a…”
Get full text

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors by Stewart, Clinton F., Tagen, Michael, Schwartzberg, Lee S., Blakely, L. Johnetta, Tauer, Kurt W., Smiley, Linda M.

“…Purpose Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC)…”
Get full text

Building Efficiency and Scaling With a Remote Genetic Counseling Program by Rao, Smita K, Blakely, L Johnetta, Small, Kate, Schleicher, Stephen, Natalie R Dickson Md

“…Purpose A third-party telemedicine (TM) genetic counseling program was initiated at a large community oncology practice spanning 35 clinical sites with 110…”
Get more information

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer by Langer, Corey J, Albert, Istvan, Ross, Helen J, Kovacs, Peter, Blakely, L. Johnetta, Pajkos, Gabor, Somfay, Attila, Zatloukal, Petr, Kazarnowicz, Andrzej, Moezi, Mehdi M, Schreeder, Marshall T, Schnyder, Judy, Ao-Baslock, Ada, Pathak, Ashutosh K, Berger, Mark S

“…Highlights • Addition of obatoclax to standard regimen failed to significantly improve outcome. • Clinical benefit (ORR + stable disease) trended better with…”
Get full text

A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer by BLAKELY, L. Johnetta, BUZDAR, Aman, CHANG, Hsiu-Yin, FRYE, Debra, THERIAULT, Richard, VALERO, Vicente, RIVERA, Edgardo, BOOSER, Daniel, KURITANI, Jun, TSUDA, Masuhiro

“…Purpose: TAS-108 is a novel steroidal anti-estrogen compound that has a strong binding affinity to the estrogen receptor and, in preclinical studies, has…”
Get full text

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer by Schwartzberg, Lee S, Wang, Grace, Somer, Bradley G, Blakely, L. Johnetta, Wheeler, Benton M, Walker, Mark S, Stepanski, Edward J, Houts, Arthur C

“…Micro-Abstract We present results of a phase II study of 41 patients with hormone-positive, HER2-negative metastatic breast cancer (MBC), who received…”
Get full text

Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence by Blakely, L. Johnetta, Buzdar, Aman U., Lozada, Jose A., Shullaih, Samer A., Hoy, Emma, Smith, Terry L., Hortobagyi, Gabriel N.

“…BACKGROUND The goal of the current study was to assess the effect of pregnancy on the subsequent risk of recurrence after treatment for breast carcinoma,…”
Get full text

The effect of COVID-19 on revenue cycle staff by Poole, Stacey L, Blakely, Johnetta, Crouse, Cheryl, Colangelo, Pam, Dickson, Natalie R.

“…Abstract only 42 Background: The COVID-19 pandemic caused a public health emergency declaration in March 2020. A safer at home order was issued by the…”
Get full text

Impact of embedded palliative care providers compared to externally available palliative care services on the number of patients receiving palliative care referrals in a large community oncology practice by Young, Garrett, Lyss, Aaron J., Blakely, Johnetta, Owens, Leah, Dickson, Natalie R., Schleicher, Stephen Matthew

“…Abstract only 12103 Background: Palliative care improves quality of life and may increase overall survival in patients with solid tumor malignancies. Despite…”
Get full text

Use of antiemetic prophylaxis and oral breakthrough medication for highly emetogenic chemotherapy (HEC) in a large community oncology network by Young, Garrett, Schleicher, Stephen Matthew, Arrowsmith, Edward, McCullough, Stacey, Richey, Sylvia S., Blakely, Johnetta, Dickson, Natalie R., Schwartzberg, Lee S.

“…Abstract only 253 Background: Prophylaxis for highly emetogenic chemotherapy (HEC) is well established in clinical guidelines, but real-world treatment…”
Get full text

Finding value in social media: A collaborative online communication platform linking providers to education and an online tumor board across a large community of oncology practices by Daniel, Davey B., Blakely, Johnetta, Schleicher, Stephen Matthew, Allen, Duncan, Marsden, Mary Catherine, Arrowsmith, Mary Margaret, Grothey, Axel, Schwartzberg, Lee S.

“…Abstract only 305 Background: Clinical collaboration across fragmented and often small clinic sites can be challenging. As a potential solution, OneOncology, a…”
Get full text

Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC) by Blakely, Johnetta, Gordan, Lucio N., Schwartzberg, Lee S., Gutman, Jacqueline, Adamson, Blythe J.S., Bourla, Ariel B., Meropol, Neal J., Ramsey, Scott David, Green, Robert J.

“…Abstract only 2061 Background: Increasing enrollment in clinical trials remains a national priority, yet there are limited data from COCs on the degree to…”
Get full text

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer by Blakely, L. Johnetta, Schwartzberg, Lee, Keaton, Mark, Schnell, Fred, Henry, David, Epperson, Amanda, Walker, Mark S

“…Abstract Pemetrexed and gemcitabine are both active agents for the treatment of locally advanced or metastatic NSCLC. We tested a novel biweekly combination of…”
Get full text

Molecular Analysis of Non―Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition by GUALBERTO, Antonio, DOLLED-FILHART, Marisa, LANGER, Corey J, BLAKELY, Johnetta, GARLAND, Linda, PAZ-ARES, Luis G, KARP, Daniel D, LEE, Adrian V, GUSTAVSON, Mark, CHRISTIANSEN, Jason, WANG, Yu-Fen, HIXON, Mary L, REYNOLDS, Jennifer, MCDONALD, Sandra, ANG, Agnes, RIMM, David L

“…This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR)…”
Get full text

Implementation of a telemedicine-based genetic counseling program in a large community oncology practice by Rao, Smita K., Blakely, L. Johnetta, Small, Kate, Schleicher, Stephen Matthew, Dickson, Natalie R.

“…393 Background: Genetic testing is an integral part of cancer care. To optimally facilitate testing, genetic counselors (GC) provide interpretation and…”
Get full text